Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study.
(2020) Journal of the European Academy of Dermatology and Venereology — Vol. 34, n° 10, p. e644-e646 (2020)
Files
2020_Fougerousse_J_Eur_Acad_Dermatol_Venereol.pdf
Preprint
Open Access - Adobe PDF
- 5.46 MB
Details
- Authors
Fougerousse, Anne-Claire 
- Abstract
- Guselkumab (Tremfya , Janssen Biotech, Inc., Horsham, PA, USA) is an anti-IL-23 p19 antibody, recently marketed for the management of moderate to severe psoriasis in adults. To date, there are only limited post-marketing data available on its effectiveness and tolerance. A retrospective, real-life multicenter study conducted in France and Belgium evaluated guselkumab tolerance and effectiveness at Month 4 (M4) in the treatment of cutaneous psoriasis, and to describe patient characteristics at baseline and after 4 months of treatment. Collected data included socio-demographic characteristics, psoriasis history (age at beginning, clinical type, associated psoriatic arthritis, previous treatments), comorbidities, psoriasis severity at beginning of treatment (PASI, PGA, DLQI) as well as about tolerance. A total of 194 patients were included; data was analyzed for 180 (14 were excluded due to missing PASI at inclusion or at M4).
- Affiliations
Citations
Fougerousse, A.-C., Ghislain, P.-D., Reguiai, Z., Maccari, F., Parier, J., Bouilly Auvray, D., Chaby, G., Pallure, V., Schmutz, J.-L., Clément, C., Jacobzone, C., Begon, E., & Esteve, E. (2020). Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. Journal of the European Academy of Dermatology and Venereology, 34(10), e644-e646. https://doi.org/10.1111/jdv.16511 (Original work published 2020)